Evaluating a Next Generation LBP Therapy for Patients with Dravet and ALS
Time: 12:45 pm
day: Day One Track A AM
Details:
- IrisRx – a platform for mechanistic based LBP drug development
- Rational selection of BL-001 strains in drug-resistant epilepsy and ALS
- Results of a pilot study with BL-001 in healthy volunteers
